Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | UGT1A3 | P35503 | 1/20 | 0.56 |
| ▸ | UGT1A8 | Q9HAW9 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963264 | 0.85 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8HDAC1 | |
| SCHEMBL2962824 | 0.84 | JUN (0.56) | JUNUGT1A1UGT1A3UGT1A8ADRB3 | |
| SCHEMBL2966592 | 0.84 | JUN (0.57) | JUNUGT1A1UGT1A3UGT1A8HPGD | |
| SCHEMBL2960177 | 0.83 | JUN (0.56) | JUNUGT1A1UGT1A3UGT1A8HPGD | |
| SCHEMBL2956891 | 0.83 | JUN (0.67) | JUNUGT1A1UGT1A3UGT1A8HPGD | |
| SCHEMBL6829363 | 0.82 | JUN (0.60) | JUNUGT1A1UGT1A3UGT1A8HPGD | |
| SCHEMBL2967715 | 0.81 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL2967720 | 0.81 | JUN (0.59) | JUNUGT1A1UGT1A3UGT1A8 | |
| SCHEMBL2963266 | 0.80 | JUN (0.60) | JUNUGT1A1UGT1A3UGT1A8HDAC1 | |
| SCHEMBL2970244 | 0.80 | JUN (0.57) | JUNUGT1A1UGT1A3UGT1A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | JUN 3/4885UGT1A1 1244/4885UGT1A3 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.